Us Congress 2023-2024 Regular Session

Us Congress House Bill HB7716

Introduced
3/19/24  
Refer
3/19/24  

Caption

To amend title XVIII of the Social Security Act to provide for enforcement of standards for reasonable and relevant contract terms and conditions and essential retail pharmacy protections under the Medicare program.

Impact

The enactment of HB 7716 would introduce significant changes to how Medicare-related pharmacy contracts are enforced. By mandating the Secretary to establish a structured allegation submission process by 2028, the bill addresses the power disparity between retail pharmacies and larger PDP sponsors. Notably, this process will enable pharmacies to report alleged violations while safeguarding them from repercussions such as frivolous allegation claims. Furthermore, the bill enforces penalties against PDP sponsors that fail to adhere to contract standards, thereby encouraging compliance and improving the financial viability of independent pharmacies, which play a crucial role in community healthcare services.

Summary

House Bill 7716 aims to amend Title XVIII of the Social Security Act by introducing enforcement mechanisms for reasonable and relevant contract terms and conditions specifically pertaining to essential retail pharmacies under the Medicare program. This bill seeks to ensure that independent community pharmacies are protected and compensated appropriately when engaging in contracts with Prescription Drug Plan (PDP) sponsors. Through defined processes for submitting contract violation allegations, the bill establishes a framework intended to empower pharmacies and enhance oversight over contracting practices within the Medicare system.

Contention

Despite the potential benefits outlined by supporters of HB 7716, the bill may not be without contention. Critics may raise concerns regarding the administrative burden it could place on both pharmacies and PDP sponsors as they navigate new compliance requirements. Furthermore, there may be apprehensive voices questioning how effectively the enforcement mechanisms will function in practice and whether they will indeed lead to enhanced protections or simply add layers of complexity to the existing regulatory framework. Ultimately, the ongoing discussions surrounding the bill will be essential to shaping the final impact it will have on the Medicare program and the communities reliant upon independent pharmacies.

Companion Bills

US SB3430

Related Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Similar Bills

US HB8574

340B ACCESS Act 340B Affording Care for Communities and Ensuring a Strong Safety-net Act

US SB927

Protecting Pharmacies in Medicaid Act

US HB8261

Preserving Telehealth, Hospital, and Ambulance Access Act

US HB1768

Lower Costs for Everyday Americans Act Nationwide Consumer and Fuel Retailer Choice Act Recycling and Composting Accountability Act SUPPORT for Patients and Communities Reauthorization Act of 2025 American Music Tourism Act Deploying American Blockchains Act

US HB7635

The 340B PATIENTS Act of 2024 The 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2024

US SB5021

340B PATIENTS Act of 2024 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2024

US HB2041

Hidden Fee Disclosure Act of 2025

US HB4507

Transparency in Coverage Act